ArticleRSC advances2019
Retracted Article: Structural characterization and anti-inflammatory potency of
Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 10 citations in OpenAlex.
- Retraction: Structural characterization and anticancer potency of centipede oligopeptides in human chondrosarcoma cancer: inducing apoptosis.RSC advances · 2023Article
- Article
- Anti-inflammatory activities of arthropod peptides: a systematic review.The journal of venomous animals and toxins including tropical diseases · 2021Review
Corrections and comments
- Retracted
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scorpion venom represents a significant source of bio-active peptides. However, the anti-inflammatory potency of scorpion venom oligopeptides (CMOs) has not been well explored. In the current study, thirty-five CMOs were isolated, the amino acid sequences were identified, and the anti-inflammatory potency was further explored in lipopolysaccharide (LPS)-induced RAW264.7 macrophages. The results showed that CMO-1 (His-Tyr-Gly-His) demonstrated the best anti-inflammatory potency by attenuating inflammatory cytokine (NO, TNF-α, IL-6, and IL-1β) production. CMO-1 also inhibited IκBα degradation and p65 nuclear translocation and suppressed NF-κB activation. Moreover, CMO-1 inhibited the phosphorylation of ERK, JNK, and p38 MAPKs. It is worth noting that CMO-1 exhibited anti-inflammatory potency; thus, it is a potential anti-inflammatory agent.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.